ZYNRELEF KIT (Bupivacaine; Meloxicam) Patent Expiration, LOE Window & CMS Spending
ZYNRELEF KIT (Bupivacaine; Meloxicam) by Heron Therapeutics: FDA Orange Book core substance LOE 2035-04-20 (last listed 2036-04-21), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Heron Therapeutics |
| FDA Application & Pathway | N211988 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2035-04-20 |
| Last Listed Patent or Exclusivity Date | 2036-04-21 |
| Orange Book Patents (*PED Extensions) | 64 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |